Related references
Note: Only part of the references are listed.Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration Results From the IRIS Registry and Komodo Healthcare Map
Arshad M. Khanani et al.
JAMA OPHTHALMOLOGY (2022)
Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER
Michael Singer et al.
OPHTHALMOLOGY RETINA (2022)
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab Post Hoc Review of HAWK and HARRIER
Jordi Mones et al.
OPHTHALMOLOGY (2021)
Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence
Vincent Daien et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2021)
Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment
Caroline R. Baumal et al.
OPHTHALMOLOGY RETINA (2021)
Restructuring Wet Age-Related Macular Degeneration Services During the COVID-19 Pandemic to Allow Social Distancing Outpatient Clinics (SDOC)
Markus Groppe et al.
CLINICAL OPHTHALMOLOGY (2021)
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
Pravin U. Dugel et al.
OPHTHALMOLOGY (2020)
Recent trends in vision impairment certifications in England and Wales
Farzana Rahman et al.
EYE (2020)
Providing a Safe and Effective Intravitreal Treatment Service: Strategies for Service Delivery
Winfried Amoaku et al.
CLINICAL OPHTHALMOLOGY (2020)
Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service
Richard P. Gale et al.
EYE (2019)
Injection site reactions with the use of biological agents
Elena Thomaidou et al.
DERMATOLOGIC THERAPY (2019)
OUTCOMES OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR THREE OR MORE YEARS A Review of Current Outcomes
Vivian L. Qin et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
The economic impact of sight loss and blindness in the UK adult population
Lynne Pezzullo et al.
BMC HEALTH SERVICES RESEARCH (2018)
Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors
Hemal Mehta et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2018)
Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set
A. Lotery et al.
EYE (2017)
Prevalence of Age-Related Macular Degeneration in Europe
Johanna M. Colijn et al.
OPHTHALMOLOGY (2017)
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration The Comparison of Age-Related Macular Degeneration Treatments Trials
Maureen G. Maguire et al.
OPHTHALMOLOGY (2016)
METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Leah N. Kim et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
The 'three-legged stool' A SYSTEM FOR SPINAL INFORMED CONSENT
J. M. Powell et al.
BONE & JOINT JOURNAL (2016)
Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion Study
Jonathan L. Prenner et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2015)
Defining response to anti-VEGF therapies in neovascular AMD
W. M. Amoaku et al.
EYE (2015)
Sir, The incidence of serious complications associated with intravitreal therapy in a quaternary ARMD service (2008-2014)
P. S. Severn et al.
EYE (2015)
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
Ursula Schmidt-Erfurth et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010
Rupert R. A. Bourne et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
\Mechanisms of age-related macular degeneration and therapeutic opportunities
Menno van Lookeren Campagne et al.
JOURNAL OF PATHOLOGY (2014)
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration Ninety-Six-Week Results of the VIEW Studies
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2014)
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature
K. Ghasemi Falavarjani et al.
EYE (2013)
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
Usha Chakravarthy et al.
LANCET (2013)
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
Daniel F. Martin et al.
OPHTHALMOLOGY (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Usha Chakravarthy et al.
OPHTHALMOLOGY (2012)
Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration
Shaker A. Mousa et al.
BIODRUGS (2010)
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
David M. Brown et al.
OPHTHALMOLOGY (2009)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
